Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study is being done to test whether panitumumab, in combination with chemotherapy and
radiation is safe in people with head and neck cancer. Another goal of this study is to find
the highest dose of the study drugs that can be given safely without causing serious sife
effects. Panitumumab is a type of drug called a monoclonal antibody that has been studied in
other types of cancers, such as kidney and colon. This monoclonal antibody is directed
against the epidermal growth factor receptor (EGFR). EGFR has been found on the majority of
head and neck cancer cells. By blocking EGFR, this monoclonal antibody may inhibit the growth
of head and neck cancer cells.